All vaccines work by teaching our bodies to recognise and fight the pathogen in a safe way. They encourage our immune system to produce antibodies, T-cells or both, so that if we encounter the infection later our immune system knows how to defend against it.
Vaccines can be made using many different technologies. The Covid-19 vaccines that are currently the most advanced are using four different approaches:
A harmless virus is altered by introducing part of the disease-causing virus’ genetic code, such as the code for Covid-19’s ‘spike’ protein.
The harmless virus transports the code into our cells – in a similar way to RNA vaccines – which then start to produce the protein.
This triggers an immune response, priming our immune system to attack the real virus later.
Oxford-AstraZeneca is the first viral vector vaccine to be approved for Covid-19. More are in late-stage research, such as CanSino Biologics, Gamaleya Research Institute and Johnson & Johnson. They all use adenoviruses – a group of viruses that cause the common cold – as the vector or carrier.
Another example of a viral vector vaccine is the Ervebo (rVSV-ZEBOV) Ebola vaccine – it uses the vesicular stomatitis virus as the carrier.
Messenger RNA is a sequence of genetic code which our bodies use all the time – it tells our cells what proteins to build so they can function.
To produce an RNA vaccine, scientists develop a synthetic version of the virus’ messenger RNA.
When this is injected into our bodies, cells read it as an instruction to start building the relevant viral protein, for example Covid-19's 'spike' protein. This prompts our immune system to respond, and in doing so it learns how to protect against future Covid-19 infection.
Two RNA Covid-19 vaccines have been approved for use: Pfizer-BioNTech and Moderna. Both have reported high levels of vaccine efficacy – around 95%.
They are the first RNA vaccines ever to be approved for use against any disease. However, researchers have been using the technology for a while, and people have been given RNA vaccines in clinical trials for other diseases, like cancer.
These vaccines could be:
These vaccines cannot cause the disease, but will cause our bodies to produce an immune response which will protect against future infection.
Some of the most advanced inactivated Covid-19 vaccines in development include Sinovac, Bharat Biotech and two by Sinopharm. Examples of existing inactivated vaccines include the whooping cough, rabies and hepatitis A vaccines.
One vaccine in phase III clinical trials is virus-like particle: Medicago Inc. An example of an existing vaccine is the HPV/cervical cancer vaccine.
A small piece of the virus’ genetic code is inserted into another cell – perhaps a bacterial, yeast, mammalian or insect cell. The code contains instructions for this cell to start building the virus protein, for example the Covid-19 ‘spike’ protein.
Cells like this act as factories, building large quantities of the protein – which is then extracted, purified and used as the active ingredient in the vaccine.
When it is injected, our bodies learn to recognise the viral protein so that they can mount an immune response which protects against future infection.
Some of the most advanced Covid-19 vaccines using this approach include Novavax and Chinese Academy of Sciences.
An example of an existing protein subunit vaccine is for hepatitis B, which uses yeast cells to build the virus protein.
To overcome the pandemic, we have to overcome it everywhere in the world. But we will only succeed if vaccines are available and affordable to all countries.
The COVID-19 Vaccine Global Access Facility (COVAX) is working to make this happen, by ensuring that all participating countries, regardless of income levels, will have equal access to the vaccines in its portfolio once they are developed. But only three of the vaccines currently in phase III clinical trials are part of the COVAX portfolio.
There is a serious danger that low-income countries may be shut out of vaccine access, as they are less able to procure deals directly with pharmaceutical companies. For example, wealthy countries have signed deals to buy roughly 600 million doses of the Pfizer-BioNTech vaccine (which is not part of the COVAX portfolio). This accounts for nearly half of Pfizer-BioNTech's total production capacity up to the end of 2021.
So countries that have secured large numbers of vaccine doses, like the UK, must commit to donate their suitable excess doses to COVAX, so that they too can be fairly distributed.
This explainer was first published on 8 December 2020.